-19.9%
ACHR vs MRNA
+34.8%
-54.7%
-67.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.4% | +5.4% | -3.0% | +1.9% |
| 7D | -2.3% | -1.1% | -1.2% | -2.2% |
| 30D | -11.3% | +126.1% | -137.4% | -24.4% |
| 3M | +5.3% | +190.0% | -184.7% | -17.6% |
| 6M | -13.2% | +157.2% | -170.4% | -29.9% |
| YTD | -25.8% | +388.2% | -414.0% | -51.2% |
| 1Y | -34.3% | +467.0% | -501.3% | -59.1% |
| 3Y | -19.9% | +36.1% | -56.0% | -37.1% |
| All | -19.9% | +34.8% | -54.7% | -37.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling